上海凱寶(300039.SZ)：公司的實控人、控股股東變更為穆竟偉
格隆匯11月7日丨上海凱寶(300039.SZ)公佈，公司於2019年11月7日收到原控股股東、實際控制人穆來安的繼承人張豔琪和穆竟偉(“信息披露義務人”)出具的《詳式權益變動報告書》。
2019年5月7日，公司原實際控制人、控股股東穆來安逝世。根據《中華人民共和國婚姻法》、《中華人民共和國繼承法》規定，經家屬協商並經河南省新鄉縣公證處出具的(2019)豫新縣證內民字第561號《公證書》、(2019)豫新縣證內民字第561-1號《公證書》、(2019)豫新縣證內民字第561-2號《公證書》，穆來安直接持有的公司股份約3.2158億股(佔公司股份總數的30.01%)，通過公司直接股東新鄉市凱誼實業有限公司(該直接股東持有上海凱寶8.26%的股份)間接持有公司3931.5659萬股(佔公司股份總數的3.67%)，前述直接及間接持有的公司權益均為其與配偶張豔琪的夫妻共同財產，張豔琪享有該等股份的50%，剩餘50%均由穆來安次女穆竟偉作為穆來安的繼承人繼承。
根據河南省新鄉縣公證處出具的(2019)豫新縣證內民字第599號《公證書》，張豔琪現將本人直接持有的上海凱寶藥業股份有限公司全部約1.6079億股股份、本人直接持有的新鄉市凱誼實業有限公司18.60%的股權、河南省聯誼製藥有限公司17.65%的股權所代表的股東表決權、提案權、提名權等股東權利，均全部委託給本人女兒穆竟偉獨立行使。
此次權益變動後，上海凱寶的實際控制人、控股股東變更為穆竟偉。除上述外，此次權益變動不存在其他安排。
公司原實際控制人、控股股東穆來安作為公司創始人，歷任上海凱寶藥業有限公司董事長、公司董事，為公司的創立、發展壯大恪盡職守、鞠躬盡瘁，堅持“誠信做藥，良藥救人”的理念，不忘初心，傾其畢生精力為公司發展做出了不可磨滅的貢獻，奠定了公司長期、穩定、健康發展的基石。其女兒穆竟偉於2008年8月起擔任公司董事會祕書，後陸續被聘任為公司副總經理、董事長。此次權益的變更，不會對公司的經營理念、經營方針和戰略規劃產生重大影響。公司管理團隊穩定，經營情況良好，公司將繼續提升綜合治理與可持續發展能力，為股東創造更大的價值
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
